ADAP

In a report released on September 9, Mara Goldstein from Mizuho Securities maintained a Hold rating on Adaptimmune Therapeutics (ADAP - Research Report), with a price target of $9.00. The company's shares closed last Friday at $1.92.Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics. According to TipRanks, Goldstein has an average return of 2.7% and a 35.69% success rate on recommended stocks. In addition to Mizuho Securities, Adaptimmune Therapeutics also received a Hold from SVB Securities's Jonathan Chang in a report issued on September 5. However, on September 9, Roth Capital maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP).
https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-hold-rating-on-adaptimmune-therapeutics-adap?utm_source=advfn.com&utm_medium=referral